$784 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 128 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 102.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LMNS | Exit | LUMENIS LTD | $0 | – | -245 | -100.0% | 0.00% | – |
| TTHI | Exit | TRANSITION THERAPEUTICS INC | $0 | – | -70,273 | -100.0% | -0.01% | – |
| PRGO | Exit | PERRIGO CO PLC | $0 | – | -273 | -100.0% | -0.02% | – |
| EARS | Exit | AURIS MED HLDG AG | $0 | – | -63,967 | -100.0% | -0.03% | – |
| ZSAN | Exit | ZOSANO PHARMA CORP | $0 | – | -62,300 | -100.0% | -0.04% | – |
| GALT | Exit | GALECTIN THERAPEUTICS INC | $0 | – | -205,000 | -100.0% | -0.06% | – |
| SPNS | Exit | SAPIENS INTL CORP N V | $0 | – | -56,420 | -100.0% | -0.06% | – |
| IPXL | Exit | IMPAX LABORATORIES INC | $0 | – | -15,000 | -100.0% | -0.07% | – |
| IMMU | Exit | IMMUNOMEDICS INC | $0 | – | -245,000 | -100.0% | -0.10% | – |
| VFC | Exit | V F CORP | $0 | – | -17,600 | -100.0% | -0.12% | – |
| BRCM | Exit | BROADCOM CORPcl a | $0 | – | -24,894 | -100.0% | -0.13% | – |
| Exit | APTOSE BIOSCIENCES INC | $0 | – | -221,096 | -100.0% | -0.14% | – | |
| TW | Exit | TOWERS WATSON & COcl a | $0 | – | -12,807 | -100.0% | -0.16% | – |
| TTPH | Exit | TETRAPHASE PHARMACEUTICALS I | $0 | – | -49,500 | -100.0% | -0.23% | – |
| SNA | Exit | SNAP ON INC | $0 | – | -15,340 | -100.0% | -0.24% | – |
| TRVN | Exit | TREVENA INC | $0 | – | -410,000 | -100.0% | -0.25% | – |
| OTIC | Exit | OTONOMY INC | $0 | – | -113,000 | -100.0% | -0.25% | – |
| Exit | MEDICINES COcall | $0 | – | -1,000 | -100.0% | -0.28% | – | |
| AAPL | Exit | APPLE INC | $0 | – | -23,223 | -100.0% | -0.28% | – |
| TKMR | Exit | TEKMIRA PHARMACEUTICALS CORP | $0 | – | -255,000 | -100.0% | -0.30% | – |
| MLNX | Exit | MELLANOX TECHNOLOGIES LTD | $0 | – | -62,850 | -100.0% | -0.30% | – |
| AGTC | Exit | APPLIED GENETIC TECHNOL CORP | $0 | – | -200,124 | -100.0% | -0.30% | – |
| PAY | Exit | VERIFONE SYS INC | $0 | – | -93,055 | -100.0% | -0.31% | – |
| OCUL | Exit | OCULAR THERAPEUTIX INC | $0 | – | -160,000 | -100.0% | -0.33% | – |
| KRE | Exit | SPDR SERIES TRUSTs&p regl bkg | $0 | – | -80,080 | -100.0% | -0.35% | – |
| SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -1,235,000 | -100.0% | -0.36% | – |
| RCPT | Exit | RECEPTOS INC | $0 | – | -20,000 | -100.0% | -0.37% | – |
| MDVN | Exit | MEDIVATION INC | $0 | – | -34,115 | -100.0% | -0.38% | – |
| FEZ | Exit | SPDR INDEX SHS FDSeuro stoxx 50 | $0 | – | -104,920 | -100.0% | -0.38% | – |
| MDCO | Exit | MEDICINES CO | $0 | – | -180,000 | -100.0% | -0.50% | – |
| EWG | Exit | ISHARESmsci germany etf | $0 | – | -192,630 | -100.0% | -0.53% | – |
| BCOMF | Exit | B COMMUNICATIONS LTD | $0 | – | -5,977,000 | -100.0% | -0.63% | – |
| VRNT | Exit | VERINT SYS INC | $0 | – | -139,434 | -100.0% | -0.83% | – |
| CXRX | Exit | CONCORDIA HEALTHCARE CORP | $0 | – | -100,000 | -100.0% | -0.88% | – |
| Exit | BIOMARIN PHARMACEUTICAL INCcall | $0 | – | -1,000 | -100.0% | -1.34% | – | |
| Exit | PERRIGO CO PLCcall | $0 | – | -1,000 | -100.0% | -1.81% | – | |
| MRK | Exit | MERCK & CO INC NEW | $0 | – | -400,000 | -100.0% | -2.23% | – |
| Exit | TEVA PHARMACEUTICAL INDS LTDcall | $0 | – | -6,500 | -100.0% | -3.76% | – | |
| Exit | ISHARES TRput | $0 | – | -13,865 | -100.0% | -16.96% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.